Cognito Therapeutics is a Cambridge, Massachusetts clinical-stage neurotechnology company spun out of MIT that develops non-invasive, wearable therapy for neurodegenerative disease. Its lead product, Spectris, delivers precise gamma-frequency light and sound stimulation through connected glasses and headphones to evoke gamma brain oscillations, with the goal of slowing cognitive and functional decline in Alzheimer's disease. Spectris AD holds FDA Breakthrough Device Designation and is being evaluated in the HOPE Study, described as the largest medical device trial focused solely on Alzheimer's disease.
Theradaptive is a clinical-stage biotech in Frederick, Maryland that re-engineers therapeutic proteins so they bind to materials and stay exactly where a surgeon places them. Its lead protein, AMP2, is a material-binding variant of the bone-growth protein rhBMP-2; combined with an implantable scaffold it becomes OsteoAdapt, a regenerative product being tested in spinal fusion, dental, and orthopedic procedures. Founded by MIT-trained Army veteran Luis Alvarez after seeing battlefield injuries, the company aims to make biologics safer by keeping them on-target.